Recent News

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

May 2, 2016
Not Flagship

Visterra Appoints Two Industry Leaders to its Board of Directors

April 21, 2016
Not Flagship

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

April 20, 2016
Not Flagship

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

April 18, 2016
Not Flagship

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

April 18, 2016
Not Flagship

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

April 13, 2016
Not Flagship

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

April 7, 2016
Not Flagship

Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results

March 30, 2016
Not Flagship

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

March 30, 2016
Not Flagship

Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer

March 28, 2016
Not Flagship

Quanterix Raises $46 Million in Series D Financing

March 23, 2016
Not Flagship

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

March 15, 2016
Not Flagship

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

March 3, 2016
Not Flagship

Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

February 25, 2016
Not Flagship

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

February 25, 2016

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

February 23, 2016
Not Flagship

Oasys Water Continues Expansion of Global Operations to Deliver Treatment Innovation to the Middle East

February 23, 2016
Not Flagship

Transmedics Announces the World's First Human Liver Transplantation Using the Organ Care System (OCS™) Liver Technology and the Initiation of the OCS™ Liver Protect U.S. Pivotal Trial

February 23, 2016
Not Flagship

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

February 18, 2016
Not Flagship

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

February 16, 2016
Not Flagship

T2 Biosystems Reports 2015 Fourth Quarter, Full Year Results

February 16, 2016
Not Flagship

Quanterix’s Simoa Technology Demonstrates Ability to Analyze Single Cancer Cells

February 10, 2016
Not Flagship

AZD2811 ACCURINS® Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

February 10, 2016
Not Flagship

Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases

February 9, 2016
Not Flagship

Editas Medicine Announces Pricing of Initial Public Offering

February 3, 2016
Not Flagship

Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors

January 29, 2016
Not Flagship

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

January 27, 2016
Not Flagship

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

January 27, 2016
Not Flagship

Quanterix Announces Expansion into Asia Pacific

January 27, 2016
Not Flagship

Black Duck’s 2015 Growth Spurs Major Expansion at Burlington Headquarters

January 27, 2016
Not Flagship

Codiak BioSciences Closes $61 Million Series B Financing

January 26, 2016
Not Flagship

Strong 2015 Places Joule as a Global Leader in Scalable Ultra-Low Carbon Fuel Technologies

January 21, 2016
Not Flagship

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

January 14, 2016
Not Flagship

Moderna Therapeutics Teams with Gates Foundation to Advance mRNA-Based Antibody Combination to Help Prevent HIV Infection

January 12, 2016
Not Flagship

Black Duck Adds Container Scanning Capabilities to Hub Security Solution

January 12, 2016
Not Flagship

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

January 12, 2016
Not Flagship

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science

January 11, 2016
Not Flagship

Moderna Licenses New Vaccine Candidates Against a New Viral Target to Merck

January 11, 2016
Not Flagship

AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

January 11, 2016
Not Flagship

Agios Outlines Key 2016 Goals and Priorities

January 11, 2016
Not Flagship

Evelo Therapeutics Establishes Core Executive Team

January 11, 2016
Not Flagship

Moderna Announces Transition to a Clinical Stage Company, Provides Business Updates and Outlines 2016 Strategic Priorities

January 11, 2016
Not Flagship

Moderna Therapeutics and PPD Announce Strategic Collaboration to Support Clinical Development of Novel mRNA Therapeutics

January 8, 2016
Not Flagship

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

January 7, 2016
Not Flagship

Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer

January 6, 2016
Not Flagship

Editas Medicine Expands Leadership Team with Key Organizational Appointments

January 5, 2016
Not Flagship

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

December 23, 2015
Not Flagship

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

December 18, 2015
Not Flagship

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

December 16, 2015
Not Flagship

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

December 15, 2015
Not Flagship

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

December 14, 2015
Not Flagship

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

December 14, 2015
Not Flagship

EcoSense Lighting Acquires Journee Lighting

December 11, 2015
Not Flagship

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

December 11, 2015
Not Flagship

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

December 11, 2015
Not Flagship

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2015
Not Flagship

Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics™

December 9, 2015
Not Flagship

Black Duck Names Jukka Alanen VP of Business Development and Corporate Strategy

November 24, 2015
Not Flagship

ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences

November 17, 2015
Not Flagship

Joule and Red Rock Biofuels Announce Intent to Merge, Creating an Industry-Leading Carbon-Neutral Fuel Production Platform

November 12, 2015
Not Flagship

Seres Therapeutics Appoints Kurt Graves to Board of Directors

November 10, 2015
Not Flagship

Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform

November 10, 2015
Not Flagship

UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

November 9, 2015
Not Flagship

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

November 8, 2015
Not Flagship

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

November 5, 2015
Not Flagship

Agios Reports Third Quarter 2015 Financial Results

November 5, 2015
Not Flagship

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

November 4, 2015
Not Flagship

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

November 4, 2015
Not Flagship

T2 Biosystems Appoints Chief Commercial Officer

November 3, 2015
Not Flagship

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

November 3, 2015
Not Flagship

T2 Biosystems Announces Leading Hospitals Adopting T2Candida for Sepsis Detection

October 29, 2015
Not Flagship

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

October 27, 2015
Not Flagship

Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

October 23, 2015
Not Flagship

Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

October 22, 2015
Not Flagship

Pronutria Biosciences Appoints Garry E. Menzel, Ph.D., as Chief Business and Strategy Officer

October 19, 2015
Not Flagship

Syros Pharmaceuticals Appoints Industry Leader Marsha H. Fanucci to Its Board of Directors

October 19, 2015
Not Flagship

Agios Outlines Key Clinical Development & Research Strategies

October 16, 2015
Not Flagship

Selecta Continues to Successfully Advance Pipeline of Novel Immunotherapeutic Candidates

October 16, 2015
Not Flagship

Christopher A. Viehbacher Joins Pronutria Biosciences’ Board of Directors

October 15, 2015
Not Flagship

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

October 15, 2015
Not Flagship

BIND Therapeutics Expands Board of Directors with Appointment of Dr. Arthur Tzianabos

October 14, 2015
Not Flagship

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

October 5, 2015
Not Flagship

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

October 5, 2015
Not Flagship

Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

October 1, 2015
Not Flagship

FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015

September 30, 2015
Not Flagship

Joule Achieves U.S. EPA Registration for CO2-Recycled Ethanol

September 30, 2015
Not Flagship

WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions

September 25, 2015
Not Flagship

Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform

September 24, 2015
Not Flagship

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

September 24, 2015
Not Flagship

Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer

September 21, 2015
Not Flagship

Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

September 21, 2015
Not Flagship

Flagship Ventures Adds Internal IP Counsel

September 9, 2015
Is Flagship Story

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

September 9, 2015
Not Flagship

Dow, Honeywell and Novomer finalists for PU innovation award

September 9, 2015
Not Flagship

Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

September 9, 2015
Not Flagship

Selecta Announces $38 Million Series E Financing

September 8, 2015
Not Flagship

Denali Therapeutics Appoints Steve E. Krognes as Chief Financial Officer

September 8, 2015
Not Flagship

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

August 21, 2015
Not Flagship

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

August 18, 2015
Not Flagship

Seventh Sense Biosystems Receives Four Patent Allowances for TAP Blood Collection System in the US and Europe

August 17, 2015
Not Flagship

Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results

August 13, 2015
Not Flagship

Editas Medicine Raises $120 Million to Advance Genome Editing

August 10, 2015
Not Flagship

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

August 6, 2015
Not Flagship

Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results

August 6, 2015
Not Flagship

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

August 6, 2015
Not Flagship

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 6, 2015
Not Flagship

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update

August 5, 2015
Not Flagship

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

August 5, 2015
Not Flagship

T2 Biosystems Reports 2015 Second Quarter Results

August 4, 2015
Not Flagship

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

August 3, 2015
Not Flagship

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

July 23, 2015
Not Flagship

Joule Appoints Peter Matrai CFO, Biofuels industry veteran brings expertise in commercialization of new technologies

July 22, 2015
Not Flagship

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

July 22, 2015
Not Flagship

Red Rock Reaches Agreement with FedEx Express to Provide Biofuels for Renewable, Low-Carbon Jet Fuel

July 21, 2015
Not Flagship

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

July 1, 2015
Not Flagship

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

June 25, 2015
Not Flagship

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

June 24, 2015
Not Flagship

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

June 23, 2015
Not Flagship

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

June 23, 2015
Not Flagship

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

June 16, 2015
Not Flagship

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

June 15, 2015
Not Flagship

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

June 12, 2015
Not Flagship

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015
Not Flagship

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

June 12, 2015
Not Flagship

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

June 12, 2015
Not Flagship

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

June 12, 2015
Not Flagship

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

June 12, 2015
Not Flagship

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

June 11, 2015
Not Flagship

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

June 10, 2015
Not Flagship

Flagship Ventures Welcomes 16 VentureLabs® Fellows Commencing Its Seventh Annual Fellowship Program

June 10, 2015
Is Flagship Story

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

June 10, 2015
Not Flagship

Pronutria Biosciences Announces Key Additions to Executive Team

June 2, 2015
Not Flagship

Pronutria Biosciences Raises $39 Million in Series C Financing

May 28, 2015
Not Flagship

Seres Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults

May 28, 2015
Not Flagship

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

May 27, 2015
Not Flagship

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

May 21, 2015
Not Flagship

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

May 18, 2015
Not Flagship

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

May 18, 2015
Not Flagship

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

May 18, 2015
Not Flagship

Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases

May 14, 2015
Not Flagship

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

May 13, 2015
Not Flagship

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

May 13, 2015
Not Flagship

Moderna Launches Third Venture Company Elpidera for Rare Diseases

May 12, 2015
Not Flagship

Moderna #1 on CNBC Disruptor 50 List

May 12, 2015
Not Flagship

Joule’s CO2-Recycled Ethanol Meets U.S. and European Specifications

May 11, 2015
Not Flagship

Joule Secures $40 Million for Continued Growth

May 11, 2015
Not Flagship

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

May 8, 2015
Not Flagship

Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results

May 7, 2015
Not Flagship

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

May 7, 2015
Not Flagship

BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

May 7, 2015
Not Flagship

Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting

May 7, 2015
Not Flagship

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

May 6, 2015
Not Flagship

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

May 5, 2015
Is Flagship Story

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

May 5, 2015
Not Flagship

T2 Biosystems Reports 2015 First Quarter Results

May 5, 2015
Not Flagship